ClinicalTrials.Veeva

Menu
S

Sunnybrook Research Institute | Odette Cancer Centre - Clinical Trials

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Palbociclib
Platinum
ARV-471
PD-0332991
Enzalutamide
Sacituzumab
Doxorubicin
Cyclophosphamide
Atezolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

31 of 88 total trials

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis

Fosigotifator is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is an up to 156-week, 2-part study...

Active, not recruiting
ALS
Amyotrophic Lateral Sclerosis
Drug: Placebo
Drug: Fosigotifator

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician...

Enrolling
Metastatic HER2-positive Breast Cancer
Drug: Trastuzumab
Drug: Gemcitabine

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse....

Active, not recruiting
Cytochrome P-450
Antineoplastic Agents, Hormonal
Drug: Placebo for Abemaciclib
Drug: Abemaciclib

This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment wit...

Active, not recruiting
Muscle-invasive Bladder Cancer
Device: Signatera
Other: Placebo

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Enrolling
Alzheimer's Disease
Drug: Placebo
Drug: Remternetug

This is a multicenter, Phase 2a, open-label, 2-part study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) in c...

Active, not recruiting
HER2+/HR+ Breast Cancer
Drug: ZW25 (Zanidatamab)
Drug: Fulvestrant

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Active, not recruiting
Advanced Breast Cancer
Drug: ARV-471
Drug: Fulvestrant

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) administered as a single agent and in combi...

Enrolling
Glioma
Melanoma
Drug: PF-07799544
Drug: encorafenib

The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if...

Active, not recruiting
Breast Cancer
Drug: vepdegestrant
Drug: PF-07220060

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemipli...

Enrolling
Melanoma
Drug: Pembrolizumab
Drug: Fianlimab

The goal of this clinical trial is to test alternative dosing of niraparib in patients with newly diagnosed high-grade, advanced stage ovarian cancer...

Enrolling
Stage III Ovarian Cancer
High Grade Ovarian Serous Adenocarcinoma
Drug: Niraparib

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 in...

Enrolling
Brain Tumor
Device: Exablate
Drug: Doxorubicin

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for th...

Enrolling
Brain Tumor
Non Small Cell Lung Cancer
Drug: Iptilimumab
Device: Blood Brain Barrier Opening - Oncology

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for...

Enrolling
Glioblastoma
Glioma
Device: Focused Ultrasound (Exablate Model 4000)
Status recently updated

Multi-center, prospective, concurrently controlled, non-randomized, double-blind (patient and assessor). Treatment of large chondral lesions in the k...

Enrolling
Active, not recruiting
Knee Injuries
Cartilage Injury
Procedure: Microfracture
Device: Microfracture plus placement of Chondro-Gide® ACC

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN281...

Enrolling
Melanoma
Drug: Cemiplimab
Drug: Placebo

A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-...

Enrolling
Amyotrophic Lateral Sclerosis
Drug: placebo
Drug: MN-166

This study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with amyotrophic lateral scleros...

Enrolling
Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Amyotrophic Lateral Sclerosis (ALS)
Other: Diluent
Drug: ALN-SOD

This phase II single-armed study will examine the clinical utility of retreating patients with osimertinib, in the third-line, following first-line t...

Enrolling
Non-Small Cell Lung Cancer
Drug: Osimertinib First-Line
Drug: Osimertinib Third-Line

Trial sponsors

Pfizer logo
S
Gilead Sciences logo
InSightec logo
Regeneron Pharmaceuticals logo
Roche logo
University Health Network, Toronto logo
Jazz Pharmaceuticals logo
Lilly logo
AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems